S
Stewart B. Fleishman
Researcher at Mount Sinai St. Luke's and Mount Sinai Roosevelt
Publications - 19
Citations - 15439
Stewart B. Fleishman is an academic researcher from Mount Sinai St. Luke's and Mount Sinai Roosevelt. The author has contributed to research in topics: Placebo & Cancer. The author has an hindex of 17, co-authored 18 publications receiving 13567 citations. Previous affiliations of Stewart B. Fleishman include North Shore-LIJ Health System & Yeshiva University.
Papers
More filters
Journal ArticleDOI
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Neil K. Aaronson,Sam H Ahmedzai,Bengt Bergman,Monika Bullinger,Ann Cull,Nicole Duez,Antonio Filiberti,Henning Flechtner,Stewart B. Fleishman,Johanna C. J. M. de Haes,Stein Kaasa,M. Klee,David Osoba,Darius Razavi,Peter B. Rofe,Simon Schraub,Kommer C. A. Sneeuw,Marianne Sullivan,Fumikazu Takeda +18 more
TL;DR: The reliability and validity of the EORTC QLQ-C30 questionnaire were highly consistent across the three language-cultural groups studied: patients from English-speaking countries, Northern Europe, and Southern Europe.
Journal ArticleDOI
Screening for psychologic distress in ambulatory cancer patients
Paul B. Jacobsen,Kristine A. Donovan,Peter C. Trask,Stewart B. Fleishman,James Zabora,Frank Baker,Jimmie C. Holland +6 more
TL;DR: The authors sought to determine whether the single‐item Distress Thermometer (DT) compared favorably with longer measures currently used to screen for distress.
Journal ArticleDOI
Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial
Ellen M. Lavoie Smith,Herbert Pang,Constance Cirrincione,Stewart B. Fleishman,Electra D. Paskett,Tim A. Ahles,Linda R. Bressler,Camilo E. Fadul,Chetaye Knox,Nguyet Le-Lindqwister,Paul Gilman,Charles L. Shapiro,Charles L. Shapiro +12 more
TL;DR: Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain, and the primary hypothesis was that dulOxetine would be more effective than placebo in decreasing chemotherapy- induced peripheral neuropathic pain.
Journal ArticleDOI
Phase III Intergroup Study of Talc Poudrage vs Talc Slurry Sclerosis for Malignant Pleural Effusion
Carolyn M. Dresler,Jemi Olak,James E. Herndon,William G. Richards,Ernest M. Scalzetti,Stewart B. Fleishman,Kemp H. Kernstine,Todd L. Demmy,David M. Jablons,Leslie J. Kohman,Thomas M. Daniel,George B. Haasler,David J. Sugarbaker +12 more
TL;DR: Both methods of talc delivery are similar in efficacy; TTI may be better for patients with either a lung or breast primary; the etiology and incidence of respiratory complications from talc need further exploration.
Journal ArticleDOI
Efficacy of Dexmethylphenidate for the Treatment of Fatigue After Cancer Chemotherapy: A Randomized Clinical Trial
Elyse E. Lower,Stewart B. Fleishman,Alyse Cooper,Jerome B. Zeldis,Herbert Faleck,Zhinuan Yu,Donald C. Manning +6 more
TL;DR: In this article, Dexmethylphenidate (D-MPH; the D-isomer of methylphenidate) was evaluated for treatment of chemotherapy-related fatigue and cognitive impairment in breast and ovarian cancer patients.